Tevogen AI Initiative: Immunotherapy with AI
Source: aithority.com
Tevogentoday informed stockholders about its artificial intelligence initiative, Tevogen.AI™. The initiative seeks to incorporate machine learning and predictive modeling into Tevogen Bio’s ExacTcell™ technology. The goal is to improve target identification and pre-clinical processes, strengthen the company’s pipeline of immunotherapies, accelerate clinical timelines, and reduce development costs.
Tevogen.AI Technologies
Tevogen.AI has two proprietary technologies with patents pending. The company intends to broaden its AI initiative beyond Tevogen Bio. The company is expanding its headquarters to accommodate Tevogen.AI’s data scientists and engineers.
Tevogen CEO, Dr. Ryan Saadi, stated that Tevogen.AI’s vision extends beyond therapy development and is expected to impact multiple sectors of healthcare. He also applauded the leadership team at Tevogen.AI and its strategic partners.
Strategic Partnerships
Microsoft provides AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery. Databricks supplies data engineering and analytics capabilities to refine Tevogen’s AI models and improve predictive accuracy.
Proprietary Technology
PredicTcell™ uses AI tools to predict immunologically active peptide complexes and their interactions with T cell receptors. This drives precision in immunotherapy treatments. The PredicTcell platform uses algorithms for in-silico predictions for candidate selection across multiple diseases. It improves with each accurate prediction, expanding the understanding of T cell receptor bindings.
Tevogen.AI has developed a large database that processes millions of protein and peptide interactions spanning diseases and the human genome.
AdapTcell™ uses algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells. AdapTcell is expected to enhance the understanding of immune responses and open therapeutic avenues. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map.
Tevogen.AI plans to use its PredicTcell and AdapTcell platforms to identify clinical trial patients, drive efficiency, reduce costs, and deliver targeted results.
Tevogen will provide updates on the progress of Tevogen.AI.
This press release contains forward-looking statements regarding Tevogen’s plans for its research and manufacturing capabilities, expectations regarding future growth, the healthcare and biopharmaceutical industries, and Tevogen’s product candidates for the treatment of infectious diseases and cancer.
These statements are based on expectations, assumptions, estimates, projections, and beliefs and are subject to risks, delays, and uncertainties that may cause actual results to differ. Factors include the need for additional capital, changes in markets, economic conditions, the ability to execute growth strategies, develop internal controls, achieve commercialization and development plans, keep pace with technological developments, develop therapeutics, regulatory lawsuits, preclinical studies and clinical trials, regulatory review, approval and commercial development, intellectual property protection, and Tevogen’s operating history. Do not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen does not undertake to update any forward-looking statements, except as required by applicable law.